SLM Corporation (SLM)
SLM Corporation (Sallie Mae) is the nation’s saving, planning, and paying for college company. Whether college is a long way off or just around the corner, Sallie Mae offers products that promote responsible personal finance, including private education loans, Upromise rewards, scholarship search, college financial planning tools, and online retail banking.
SLM Corporation (SLM)‘s Financial Overview
SLM Corporation (SLM) surged 1.85% yesterday to close its trading session at $11. The company has 1 year Price Target of $15.09. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 5.68 Million shares yesterday. The firm shows the market capitalization of $4.96 Billion.
The firm is trading with SMA20 of -0.95 Percent, SMA50 of SMA50 Percent and SMA200 of -0.01 percent. SLM Corporation has P/S value of 3.45 while its P/B value stands at 2.29. Similarly, the company has Return on Assets of 1.3 percent, Return on Equity of 13.8 percent and Return on Investment of 1.5 Percent. The company shows Gross Margin and Operating Margin of 76.6 percent and 34.4 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 1.6 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 11 analysts offering 12-month price forecasts for SLM Corp have a median target of 15.50, with a high estimate of 17.00 and a low estimate of 13.00. The median estimate represents a +40.91% increase from the last price of 11.00.
Novavax, Inc. (NVAX)
NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women’s health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.
Novavax, Inc. (NVAX)‘s Financial Outlook
The 6 analysts offering 12-month price forecasts for Novavax Inc have a median target of 2.00, with a high estimate of 10.00 and a low estimate of 1.50. The median estimate represents a -2.44% decrease from the last price of 2.05.
According to Zacks Investment Research, Novavax, Inc. has a Consensus Recommendation of 2.43. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock surged2.5% and closed its last trading session at $2.05. The company has the market capitalization of $649.34 Million. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 5.67 Million shares. The company has a total of 316.75 Million shares outstanding.
The company has YTD performance of 65.32 percent. Beta for Novavax, Inc. stands at 2.41 while its ATR (average true range) is 0.16. The company has Weekly Volatility of 6.26%% and Monthly Volatility of 7.81%.
Novavax, Inc. has distance from 20-day Simple Moving Average (SMA20) of -2.05%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of 45.07%.